The University of Chicago Header Logo

Connection

George Bakris to Diabetic Nephropathies

Back to Details
This is a "connection" page, showing publications George Bakris has written about Diabetic Nephropathies.
George Bakris
Connection Strength
33.668
Diabetic Nephropathies
  1. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care. 2023 09 01; 46(9):1574-1586.
    View in: PubMed
    Score: 0.769
  2. Slowing the Progression of Diabetic Kidney Disease. Cells. 2023 07 31; 12(15).
    View in: PubMed
    Score: 0.764
  3. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int. 2023 01; 103(1):196-206.
    View in: PubMed
    Score: 0.725
  4. The changing trajectory of diabetic kidney disease. Curr Opin Nephrol Hypertens. 2023 01 01; 32(1):98-102.
    View in: PubMed
    Score: 0.723
  5. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. Postgrad Med. 2023 Apr; 135(3):224-233.
    View in: PubMed
    Score: 0.699
  6. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. Curr Diab Rep. 2022 05; 22(5):213-218.
    View in: PubMed
    Score: 0.699
  7. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes Obes Metab. 2022 07; 24(7):1197-1205.
    View in: PubMed
    Score: 0.699
  8. Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. Am J Nephrol. 2021; 52(12):969-976.
    View in: PubMed
    Score: 0.682
  9. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol. 2022 01; 18(1):56-70.
    View in: PubMed
    Score: 0.676
  10. A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial. Kidney360. 2021 08 26; 2(8):1240-1250.
    View in: PubMed
    Score: 0.661
  11. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. Clin J Am Soc Nephrol. 2020 12 07; 15(12):1705-1714.
    View in: PubMed
    Score: 0.634
  12. Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician. J Fam Pract. 2020 09; 69(7 Suppl):S81-S86.
    View in: PubMed
    Score: 0.625
  13. Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease. Diabetes Obes Metab. 2020 04; 22 Suppl 1:69-76.
    View in: PubMed
    Score: 0.607
  14. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):333-344.
    View in: PubMed
    Score: 0.589
  15. Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors. Am J Kidney Dis. 2019 11; 74(5):573-575.
    View in: PubMed
    Score: 0.576
  16. Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes. Diabetes Care. 2018 04; 41(4):662-663.
    View in: PubMed
    Score: 0.528
  17. SGLT2 Inhibitors and Mechanisms of Hypertension. Curr Cardiol Rep. 2018 01 19; 20(1):1.
    View in: PubMed
    Score: 0.521
  18. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2017 09; 26(5):368-374.
    View in: PubMed
    Score: 0.507
  19. Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy. Nat Rev Nephrol. 2016 10; 12(10):583-4.
    View in: PubMed
    Score: 0.469
  20. Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy? Curr Diab Rep. 2016 Apr; 16(4):24.
    View in: PubMed
    Score: 0.460
  21. Finerenone for Albuminuria in Patients With Diabetic Nephropathy--Reply. JAMA. 2016 Jan 19; 315(3):306.
    View in: PubMed
    Score: 0.453
  22. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Blood Purif. 2016; 41(1-3):139-43.
    View in: PubMed
    Score: 0.453
  23. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 01; 314(9):884-94.
    View in: PubMed
    Score: 0.442
  24. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA. 2015 Jul 14; 314(2):151-61.
    View in: PubMed
    Score: 0.437
  25. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014; 40(6):572-81.
    View in: PubMed
    Score: 0.422
  26. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014; 40(1):64-74.
    View in: PubMed
    Score: 0.408
  27. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. Adv Chronic Kidney Dis. 2014 May; 21(3):281-6.
    View in: PubMed
    Score: 0.403
  28. Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol. 2013 Oct; 8(10):1694-701.
    View in: PubMed
    Score: 0.383
  29. Telmisartan in incipient and overt diabetic renal disease. J Nephrol. 2011 May-Jun; 24(3):263-73.
    View in: PubMed
    Score: 0.327
  30. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011 May; 86(5):444-56.
    View in: PubMed
    Score: 0.327
  31. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab. 2010 Dec; 12(12):1079-83.
    View in: PubMed
    Score: 0.318
  32. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2010; 31(5):469-70.
    View in: PubMed
    Score: 0.305
  33. Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy? Postgrad Med. 2009 Mar; 121(2):77-88.
    View in: PubMed
    Score: 0.281
  34. Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens. 2009 Mar; 18(2):107-11.
    View in: PubMed
    Score: 0.281
  35. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008 Aug; 4(8):444-52.
    View in: PubMed
    Score: 0.269
  36. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008 Jun; 73(11):1303-9.
    View in: PubMed
    Score: 0.263
  37. Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective. J Nephrol. 2007 Nov-Dec; 20(6):703-15.
    View in: PubMed
    Score: 0.257
  38. Protein kinase C-beta inhibition: a promise not yet fulfilled. Clin J Am Soc Nephrol. 2007 Jul; 2(4):619-20.
    View in: PubMed
    Score: 0.249
  39. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006 Oct; 70(7):1223-33.
    View in: PubMed
    Score: 0.235
  40. Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep. 2004 Oct; 6(5):352-6.
    View in: PubMed
    Score: 0.207
  41. How to adjust ACE inhibitors and ARBs in diabetes? Postgrad Med. 2004 May; 115(5):9-10.
    View in: PubMed
    Score: 0.201
  42. Blood pressure control and nephroprotection in diabetes. J Clin Pharmacol. 2004 Apr; 44(4):431-8.
    View in: PubMed
    Score: 0.200
  43. Diabetes and chronic kidney disease: tragedy and challenge. Blood Purif. 2004; 22(1):130-5.
    View in: PubMed
    Score: 0.197
  44. Hypertension and nephropathy. Am J Med. 2003 Dec 08; 115 Suppl 8A:49S-54S.
    View in: PubMed
    Score: 0.196
  45. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med. 2023 12; 176(12):1606-1616.
    View in: PubMed
    Score: 0.196
  46. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024 02 06; 149(6):450-462.
    View in: PubMed
    Score: 0.195
  47. How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr Hypertens Rep. 2003 Oct; 5(5):418-25.
    View in: PubMed
    Score: 0.193
  48. Role for beta-blockers in the management of diabetic kidney disease. Am J Hypertens. 2003 Sep; 16(9 Pt 2):7S-12S.
    View in: PubMed
    Score: 0.192
  49. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003 Jul 14; 163(13):1555-65.
    View in: PubMed
    Score: 0.190
  50. The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols. Postgrad Med. 2003 May; 113(5):35-40, 43-4, 50.
    View in: PubMed
    Score: 0.188
  51. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2023 03 31; 38(4):894-903.
    View in: PubMed
    Score: 0.187
  52. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. Am J Kidney Dis. 2023 07; 82(1):84-96.e1.
    View in: PubMed
    Score: 0.186
  53. Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. Diabetes Obes Metab. 2023 06; 25(6):1512-1522.
    View in: PubMed
    Score: 0.186
  54. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother. 2023 02 02; 9(2):183-191.
    View in: PubMed
    Score: 0.185
  55. When to refer patients to a nephrologist? Postgrad Med. 2003 Feb; 113(2):11.
    View in: PubMed
    Score: 0.185
  56. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003 Jan; 17(1):7-12.
    View in: PubMed
    Score: 0.184
  57. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care. 2022 12 01; 45(12):2991-2998.
    View in: PubMed
    Score: 0.182
  58. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. J Am Coll Cardiol. 2022 11 01; 80(18):1721-1731.
    View in: PubMed
    Score: 0.181
  59. ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence. J Clin Hypertens (Greenwich). 2002 Nov-Dec; 4(6):420-3.
    View in: PubMed
    Score: 0.181
  60. Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease. Clin Pharmacol Ther. 2022 Nov; 112(5):1098-1107.
    View in: PubMed
    Score: 0.179
  61. Glucose-lowering treatment patterns in patients with diabetic kidney disease. Am J Manag Care. 2022 08 01; 28(8):e301-e307.
    View in: PubMed
    Score: 0.178
  62. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant. 2022 06 23; 37(7):1261-1269.
    View in: PubMed
    Score: 0.177
  63. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022 08; 102(2):248-260.
    View in: PubMed
    Score: 0.176
  64. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Curr Hypertens Rep. 2002 Jun; 4(3):185-90.
    View in: PubMed
    Score: 0.176
  65. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2022 05 25; 37(6):1014-1023.
    View in: PubMed
    Score: 0.176
  66. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail. 2022 06; 24(6):996-1005.
    View in: PubMed
    Score: 0.176
  67. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure. JACC Heart Fail. 2022 07; 10(7):498-507.
    View in: PubMed
    Score: 0.175
  68. Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone. J Am Heart Assoc. 2022 04 05; 11(7):e025079.
    View in: PubMed
    Score: 0.174
  69. The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes Metab. 2022 07; 48(4):101331.
    View in: PubMed
    Score: 0.173
  70. Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design. Am J Nephrol. 2022; 53(1):50-58.
    View in: PubMed
    Score: 0.172
  71. Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options. J Clin Hypertens (Greenwich). 2002 Jan-Feb; 4(1):52-7.
    View in: PubMed
    Score: 0.171
  72. Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction. Prog Brain Res. 2002; 139:289-98.
    View in: PubMed
    Score: 0.171
  73. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001 Dec 10-24; 161(22):2661-7.
    View in: PubMed
    Score: 0.170
  74. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial. Clin J Am Soc Nephrol. 2021 12; 16(12):1824-1832.
    View in: PubMed
    Score: 0.170
  75. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. J Am Soc Nephrol. 2021 11; 32(11):2900-2911.
    View in: PubMed
    Score: 0.168
  76. Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clin Pharmacol Ther. 2021 06; 109(6):1631-1638.
    View in: PubMed
    Score: 0.160
  77. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020 12 31; 16(1):59-69.
    View in: PubMed
    Score: 0.159
  78. Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. Diabetes Obes Metab. 2021 02; 23(2):561-568.
    View in: PubMed
    Score: 0.159
  79. Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J Hum Hypertens. 2000 Oct-Nov; 14(10-11):667-85.
    View in: PubMed
    Score: 0.157
  80. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000 Sep; 36(3):646-61.
    View in: PubMed
    Score: 0.156
  81. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):345-356.
    View in: PubMed
    Score: 0.147
  82. When to discontinue ACE inhibitors for nephropathy. Postgrad Med. 1999 Jul; 106(1):29.
    View in: PubMed
    Score: 0.144
  83. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 06 13; 380(24):2295-2306.
    View in: PubMed
    Score: 0.142
  84. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 05 11; 393(10184):1937-1947.
    View in: PubMed
    Score: 0.142
  85. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):925-933.
    View in: PubMed
    Score: 0.138
  86. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998 Oct; 54(4):1283-9.
    View in: PubMed
    Score: 0.137
  87. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998 Sep; 54(3):889-96.
    View in: PubMed
    Score: 0.136
  88. Risks for renal involvement in diabetes. Postgrad Med. 1998 Sep; 104(3):33.
    View in: PubMed
    Score: 0.136
  89. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail. 2018 08; 5(4):592-602.
    View in: PubMed
    Score: 0.133
  90. Baseline characteristics and enrichment results from the SONAR trial. Diabetes Obes Metab. 2018 08; 20(8):1829-1835.
    View in: PubMed
    Score: 0.133
  91. Progression of diabetic nephropathy. A focus on arterial pressure level and methods of reduction. Diabetes Res Clin Pract. 1998 Apr; 39 Suppl:S35-42.
    View in: PubMed
    Score: 0.132
  92. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 06; 20(6):1369-1376.
    View in: PubMed
    Score: 0.131
  93. Are All Patients With Type 1 Diabetes Destined for Dialysis if They Live Long Enough? Probably Not. Diabetes Care. 2018 03; 41(3):389-390.
    View in: PubMed
    Score: 0.131
  94. The renin-angiotensin system in diabetic nephropathy: the endothelial connection. Miner Electrolyte Metab. 1998; 24(6):381-8.
    View in: PubMed
    Score: 0.130
  95. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997 Mar; 29(3):744-50.
    View in: PubMed
    Score: 0.122
  96. Renal mortality associated with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1997 Mar-Apr; 11(2):104-11.
    View in: PubMed
    Score: 0.122
  97. Socioeconomic impact of diabetic nephropathy: can we improve the outcome? J Hypertens Suppl. 1997 Mar; 15(2):S77-82.
    View in: PubMed
    Score: 0.122
  98. Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. J Hum Hypertens. 1997 Jan; 11(1):35-8.
    View in: PubMed
    Score: 0.121
  99. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996 Nov; 50(5):1641-50.
    View in: PubMed
    Score: 0.120
  100. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med. 1996 Aug 01; 125(3):201-4.
    View in: PubMed
    Score: 0.118
  101. Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy. Ann Pharmacother. 1996 Jul-Aug; 30(7-8):791-801.
    View in: PubMed
    Score: 0.117
  102. Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol Dial Transplant. 1995 Oct; 10 Suppl 9:56-62.
    View in: PubMed
    Score: 0.111
  103. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens Suppl. 1995 Aug; 13(2):S95-101.
    View in: PubMed
    Score: 0.110
  104. Update on blood pressure goals in diabetes mellitus. Curr Cardiol Rep. 2015 Jun; 17(6):37.
    View in: PubMed
    Score: 0.108
  105. Renal effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial. J Am Soc Nephrol. 1995 Mar; 5(9):1684-8.
    View in: PubMed
    Score: 0.107
  106. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015 Mar; 38(3):429-30.
    View in: PubMed
    Score: 0.107
  107. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014 Oct; 37(10):2864-83.
    View in: PubMed
    Score: 0.104
  108. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014 Oct; 64(4):510-33.
    View in: PubMed
    Score: 0.104
  109. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014 Oct; 16(10):1016-27.
    View in: PubMed
    Score: 0.102
  110. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int. 1994 Jul; 46(1):161-9.
    View in: PubMed
    Score: 0.102
  111. Microalbuminuria in non-insulin-dependent diabetes mellitus. Implications for renal survival. Arch Intern Med. 1994 Jan 24; 154(2):146-53.
    View in: PubMed
    Score: 0.099
  112. Antihypertensive therapy and progression of diabetic renal disease. J Cardiovasc Pharmacol. 1994; 23 Suppl 1:S34-8.
    View in: PubMed
    Score: 0.098
  113. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications. 1994 Jan-Mar; 8(1):2-6.
    View in: PubMed
    Score: 0.098
  114. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014; 37(3):867-75.
    View in: PubMed
    Score: 0.098
  115. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013 12 26; 369(26):2492-503.
    View in: PubMed
    Score: 0.097
  116. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant. 2013 Nov; 28(11):2841-50.
    View in: PubMed
    Score: 0.097
  117. Diabetic nephropathy. Dis Mon. 1993 Aug; 39(8):573-611.
    View in: PubMed
    Score: 0.096
  118. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med. 1993 Apr 26; 153(8):973-80.
    View in: PubMed
    Score: 0.094
  119. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med. 1993 Apr 15; 118(8):643-4.
    View in: PubMed
    Score: 0.094
  120. Diabetic nephropathy. What you need to know to preserve kidney function. Postgrad Med. 1993 Apr; 93(5):89-90, 93-5, 99-100.
    View in: PubMed
    Score: 0.093
  121. Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). Am J Nephrol. 2013; 37(3):212-22.
    View in: PubMed
    Score: 0.093
  122. Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol. 2013 Mar; 9(3):147-53.
    View in: PubMed
    Score: 0.092
  123. Risk for renal injury in diabetic hypertensive patients. The physiologic basis for blood pressure control. Postgrad Med. 1992 Feb 15; 91(3):77-80, 83-4.
    View in: PubMed
    Score: 0.086
  124. A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease. Arch Intern Med. 1991 Dec; 151(12):2367-72.
    View in: PubMed
    Score: 0.085
  125. The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states. J Am Soc Nephrol. 1991 Aug; 2(2 Suppl 1):S21-9.
    View in: PubMed
    Score: 0.083
  126. Do fibrates truly preserve kidney function? Nat Rev Endocrinol. 2011 Mar; 7(3):130-1.
    View in: PubMed
    Score: 0.080
  127. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med. 1990 Dec 15; 113(12):987-8.
    View in: PubMed
    Score: 0.080
  128. Prevention of microalbuminuria in patients with type 2 diabetes: what do we know? J Clin Hypertens (Greenwich). 2010 Jun; 12(6):422-30.
    View in: PubMed
    Score: 0.077
  129. Prehypertension: is it relevant for nephrologists? Kidney Int. 2010 Feb; 77(3):194-200.
    View in: PubMed
    Score: 0.074
  130. Inhibiting the renin-angiotensin system in patients with type 1 diabetes: is it worth it? Pol Arch Med Wewn. 2009 Nov; 119(11):692-3.
    View in: PubMed
    Score: 0.074
  131. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S11-21.
    View in: PubMed
    Score: 0.071
  132. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S22-31.
    View in: PubMed
    Score: 0.071
  133. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Kidney Int. 2009 Mar; 75(5):449-52.
    View in: PubMed
    Score: 0.070
  134. The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. J Hypertens. 2009 Mar; 27(3):666-9.
    View in: PubMed
    Score: 0.070
  135. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Blood Purif. 2009; 27(2):231-4.
    View in: PubMed
    Score: 0.070
  136. The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Kidney Blood Press Res. 2009; 32(1):67-70.
    View in: PubMed
    Score: 0.070
  137. The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Nephrology (Carlton). 2009 Feb; 14(1):49-51.
    View in: PubMed
    Score: 0.070
  138. The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented. Clin Exp Nephrol. 2009 Feb; 13(1):96-9.
    View in: PubMed
    Score: 0.070
  139. The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. J Hum Hypertens. 2009 Mar; 23(3):222-5.
    View in: PubMed
    Score: 0.070
  140. The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented. Pediatr Nephrol. 2009 Mar; 24(3):427-30.
    View in: PubMed
    Score: 0.070
  141. The message for World Kidney Day 2009: hypertension and kidney disease, a marriage that should be prevented. Iran J Kidney Dis. 2009 Jan; 3(1):7-10.
    View in: PubMed
    Score: 0.070
  142. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008 Aug; 74(3):364-9.
    View in: PubMed
    Score: 0.067
  143. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care. 2007 Apr; 30(4):995-6.
    View in: PubMed
    Score: 0.061
  144. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care. 2005 Nov; 28(11):2686-90.
    View in: PubMed
    Score: 0.056
  145. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005 Apr; 67(4):1483-8.
    View in: PubMed
    Score: 0.054
  146. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens. 2005 Feb; 19(2):139-44.
    View in: PubMed
    Score: 0.053
  147. Slowing the progression of diabetic nephropathy and its cardiovascular consequences. Am Heart J. 2004 Aug; 148(2):243-51.
    View in: PubMed
    Score: 0.051
  148. Management of hypertension in the cardiometabolic syndrome and diabetes. Curr Diab Rep. 2004 Jun; 4(3):199-205.
    View in: PubMed
    Score: 0.051
  149. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004 Jun; 65(6):1991-2002.
    View in: PubMed
    Score: 0.051
  150. The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2004 Mar; 13(2):155-61.
    View in: PubMed
    Score: 0.050
  151. What have we learned from the current trials? Med Clin North Am. 2004 Jan; 88(1):189-207.
    View in: PubMed
    Score: 0.049
  152. Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans. Curr Opin Nephrol Hypertens. 2003 Jan; 12(1):79-84.
    View in: PubMed
    Score: 0.046
  153. Treatment of hypertension in patients with renal disease. Cardiovasc Drugs Ther. 2002 Dec; 16(6):503-10.
    View in: PubMed
    Score: 0.046
  154. Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction. Curr Diab Rep. 2002 Jun; 2(3):258-62.
    View in: PubMed
    Score: 0.044
  155. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 03; 383(23):2219-2229.
    View in: PubMed
    Score: 0.039
  156. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020 05; 31(5):1128-1139.
    View in: PubMed
    Score: 0.038
  157. Diabetic hypertensive patients: improving their prognosis. J Cardiovasc Pharmacol. 1998; 31 Suppl 2:S34-40.
    View in: PubMed
    Score: 0.032
  158. Treatment of renal failure and blood pressure. Curr Opin Nephrol Hypertens. 1997 May; 6(3):237-42.
    View in: PubMed
    Score: 0.031
  159. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013 Aug; 62(2):201-13.
    View in: PubMed
    Score: 0.024
  160. Hypertension in diabetic patients. An overview of interventional studies to preserve renal function. Am J Hypertens. 1993 Apr; 6(4):140S-147S.
    View in: PubMed
    Score: 0.023
  161. Risk for renal injury in diabetic hypertensive patients. Pharmacologic approaches. Postgrad Med. 1992 Feb 15; 91(3):87-91, 94-5.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.